MD An­der­son, Flag­ship start­up part­ner to de­sign and test can­cer drugs made with gen­er­a­tive AI

Gen­er­ate Bio­med­i­cines, a start­up found­ed by the life sci­ence in­vest­ment com­pa­ny Flag­ship Pi­o­neer­ing, has part­nered with the Uni­ver­si­ty of Texas MD An­der­son Can­cer Cen­ter to de­vel­op pro­tein ther­a­pies made from gen­er­a­tive AI, the ar­ti­fi­cial in­tel­li­gence tech­nique that’s sweep­ing the web with text gen­er­a­tors such as Chat­G­PT and im­age gen­er­a­tors like DALL-E.

The col­lab­o­ra­tion, an­nounced Thurs­day morn­ing, will span the gamut of drug dis­cov­ery and de­vel­op­ment. The pair will ini­tial­ly iden­ti­fy up to five tar­gets in ad­vanced can­cers, in­clud­ing lung can­cer, to de­sign drugs for Gen­er­ate’s com­pu­ta­tion­al and wet labs in Somerville, MA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER